Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Thiopurine drugs like 6-Mercaptopurine (6MP) are the cornerstone of maintenance therapy in acute lymphoblastic leukemia (ALL). A recently described variant in alpha-ketoglutarate dependent dioxygenase (FTO) gene has been reported to play an important role in thiopurine induced myelosuppression.

Methods

In this study, we genotyped a coding variant (p.Ala134Thr, rs79206939) and an intronic variant (rs16952570) of FTO in 174 Indian children (age ≤ 12 years) with ALL on maintenance phase of chemotherapy and examined correlation with the risk of thiopurine induced myelosuppression and hepatic toxicity.

Results

The prevalence of FTO-rs16952570 polymorphism was 18.4% (32/174) with 142 (82%) cases having TT genotype, 26 (15%) cases with TC genotype and 6 (3.4%) cases having CC genotype. FTO-rs79206939 was absent and non-polymorphic in our study group. The mean dose of 6-MP during 36 weeks of maintenance of TT, TC and CC carriers of FTO-rs16952570 was 53.7, 53.6 and 54.1 mg/m2/day. Number of patients tolerating starting dose of 60 mg/m2/day was significantly higher in CC (50%) than TT/TC (14%) genotype carrying cases (p = 0.014). However, no statistical significance was observed for total leukocyte count (TLC), absolute neutrophil count (ANC) as well as for platelets counts in patients harboring FTO-rs16952570 TT/TC/CC genotype at 4, 8, 12, 24 and 36 weeks after start of thiopurine therapy. Further, no significant correlation was noted between number of weeks of chemotherapy interruptions or episodes of febrile neutropenia and no evidence of hepatotoxicity was found with the genotype studied.

Conclusion

Polymorphism in FTO-rs16952570 did not show any correlation with thiopurine related toxicity in ALL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data will be made available on reasonable request.

References

  1. Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet (Lond, Engl) 381:1943–1955

    Article  Google Scholar 

  2. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 30:1663–1669

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zaza G, Cheok M, Krynetskaia N et al (2010) Thiopurine pathway. Pharmacogenet Genom 20:573–574

    Article  CAS  Google Scholar 

  4. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001–2008

    Article  CAS  PubMed  Google Scholar 

  5. Lennard L (2014) Implementation of TPMT testing. Br J Clin Pharmacol 77:704–714

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yang JJ, Landier W, Yang W et al (2015) Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33:1235–1242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Moriyama T, Yang W, Smith C, Pui CH, Evans WE, Relling MV, Bhatia S, Yang JJ (2022) Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenet Genom 32:60–66

    Article  CAS  Google Scholar 

  8. Wang Q, Mailloux J, Schwarz UI, Kim RB, Wilson A (2022) A novel NUDT15 variant identified in Caucasian TPMT wild type patients with inflammatory bowel disease and azathioprine-related myelotoxicity. Pharmacogenet Genom 32:39–41

    Article  CAS  Google Scholar 

  9. Puangpetch A, Tiyasirichokchai R, Pakakasama S, Wiwattanakul S, Anurathapan U, Hongeng S, Sukasem C (2020) NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia. Pharmacogenomics 21:403–410

    Article  CAS  PubMed  Google Scholar 

  10. Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N (2019) Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 83:341–348

    Article  CAS  PubMed  Google Scholar 

  11. Wang DS, Yu CH, Lin CY et al (2021) Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants. Pediatr Res 89:217–222

    Article  CAS  PubMed  Google Scholar 

  12. Kim HS, Cheon JH, Jung ES et al (2017) A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. Gut 66:1926–1935

    Article  CAS  PubMed  Google Scholar 

  13. Chen S, Tan WZ, Sutiman N et al (2020) An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients. Pharmacogenom J 20:505–515

    Article  CAS  Google Scholar 

  14. Das N, Banavali S, Bakhshi S et al (2022) Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. https://doi.org/10.1186/S13063-022-06033-1

    Article  PubMed  PubMed Central  Google Scholar 

  15. Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36:503–517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bhatia S, Landier W, Shangguan M et al (2012) Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol 30:2094–2101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia—PubMed. https://pubmed.ncbi.nlm.nih.gov/10216075/. Accessed 6 Sep 2022

  18. Zimm S, Collins JM, Riccardi R, O’Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005–1009

    Article  CAS  PubMed  Google Scholar 

  19. Lafolie P, Hayder S, Bjork O, Ahström L, Liliemark J, Peterson C (1986) Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand 75:797–803

    Article  CAS  PubMed  Google Scholar 

  20. Sato T, Takagawa T, Kakuta Y et al (2017) NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest Res 15:328–337

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yao L, Yin H, Hong M, Wang Y, Yu T, Teng Y, Li T, Wu Q (2021) RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia 35:1243–1257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Huang H, Wang Y, Kandpal M et al (2020) FTO-dependent N 6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res 80:3200–3214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Liu J, Ren D, Du Z, Wang H, Zhang H, Jin Y (2018) m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem Biophys Res Commun 502:456–464

    Article  CAS  PubMed  Google Scholar 

  24. Li J, Han Y, Zhang H, Qian Z, Jia W, Gao Y, Zheng H, Li B (2019) The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem Biophys Res Commun 512:479–485

    Article  CAS  PubMed  Google Scholar 

  25. Zejuan Li A, Weng H, Su R, Jin J, He C, Chen J (2017) FTO plays an oncogenic role in acute myeloid leukemia as a N 6-methyladenosine RNA demethylase accession numbers GSE34184 GSE30285 GSE76414 GSE84944 GSE85008. Cancer Cell 31:127–141

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The study was funded by intramural special research grant for MD/DM from Postgraduate Institute of Medical Education & Research, Chandigarh.

Author information

Author notes

  1. Minu Singh and Divya Bhaskar have contributed equally to the study.

Authors and Affiliations

  1. Haematology-Oncology Unit, Department of Paediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Minu Singh, Divya Bhaskar, Prateek Bhatia, Rozy Thakur, Pankaj Sharma, Deepak Bansal, Richa Jain & Amita Trehan

Authors
  1. Minu Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Divya Bhaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prateek Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rozy Thakur
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pankaj Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Deepak Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richa Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amita Trehan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amita Trehan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, M., Bhaskar, D., Bhatia, P. et al. Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 92, 51–56 (2023). https://doi.org/10.1007/s00280-023-04546-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-023-04546-3

Keywords

Search

Navigation